🌐 GLP-1s vs Other Diabetes Drugs Across 181 Outcomes

Most drug comparisons answer one question at a time. A study published in the Journal of Diabetes Science and Technology asked 181 of them at once. Using a target trial emulation — a design that rebuilds a randomized trial's logic inside real health records — researchers across five University of California medical centers compared adults with type 2 diabetes who newly started a GLP-1 receptor agonist against patients starting one of three established alternatives: sulfonylureas, SGLT2 inhibitors, or DPP-4 inhibitors. The records ran from 2012 to 2025, matching was built on more than 11,000 covariates, and follow-up stretched to five years.

The bar for calling an association real was deliberately high. A finding counted only if it stayed stable when any single medical center was dropped from the analysis, carried an E-value of at least 1.5 (a measure of how much hidden bias it would take to erase it), and survived false-discovery-rate adjustment. Of 181 prespecified outcomes, 118 associations cleared every hurdle — 65 pointing to lower risk on GLP-1 therapy, 53 pointing to higher risk.

❤️ Where GLP-1s came out ahead

The cardiovascular pattern was the most consistent in the whole map: heart attack risk roughly halved (HR 0.53), with heart failure, thromboembolism (0.69–0.72), and myocarditis/cardiomyopathy also lower. Kidney outcomes leaned the same way — nephritis/nephrosis at 0.73 — alongside lower rates of nutritional anemia, coagulation disorders, and, intriguingly, tobacco-related disorders (0.60), one more datapoint for the addiction signal researchers keep seeing with this class.

🦴 Where the signals point the other way

The higher-risk side concentrated in the musculoskeletal system — 22 of the 53 increased-risk associations — led by stress fractures (1.68) and osteoarthritis (1.48). Diverticular disease (1.18–1.33), sleep-wake disorders (1.27–1.54), and menopausal disorders (1.32–1.52) also ran higher. Whether these reflect the drugs themselves, the rapid weight loss they cause, or simply more medical contact and diagnosis among GLP-1 users is exactly what follow-up work has to untangle.

Maps like this one are how a drug class grows up. The headline benefits — heart, kidney, metabolic — now have a whole-body context around them, and prescribers get a concrete list of trade-offs to weigh for the patient in front of them: a strong cardiovascular hand, played alongside honest questions about joints and bones. The next step belongs to targeted studies that can say which of these 118 signals are the drugs talking — and which are the data.